BiondVax Pharmaceuticals Ltd. BVXV
Set alert
As of Sep 6, 3:59 PM ET
52-week range unavailable
- Open
- 1.32
- Prev close
- 1.36
- Mkt cap
- 4.93M
- Vol
- 22.67K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.31
- High
- 1.36
- Forward P/E
- -0.59
- Beta
- 2.38
- Short ratio
- 0.03
- Inst. own
- 0.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 11, 2023
- 50-d avg
- 1.62
- 200-d avg
- 3.97
- 1y target
- 39.00
Key statistics
- Market cap
- 4.93M
- Enterprise value
- 17.18M
- Trailing P/E
- 0.00
- Forward P/E
- -0.59
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -4.51
- Beta
- 2.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.22M
- Total cash
- 10.80M
- Total debt
- 23.28M
- Return on equity
- -5601.53%
- Shares outstanding
- 3.28M
- Short % of float
- 0.00%
- 50-day average
- 1.62
- 200-day average
- 3.97
Analyst view
Consensus: none
- Target (low)
- 8.00
- Target (mean)
- 39.00
- Target (high)
- 70.00
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 11, 2023
Expected Aug 11, 2023. Consensus EPS estimate -0.91.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Apr 17, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 30, 2022 | Sep 1, 2022 | -0.10 | — | — | — |
| Aug 25, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| Jun 1, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 26, 2022 | Aegis Capital | init | — | Buy |
| Jun 26, 2015 | Aegis Capital | init | — | Buy |
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biondvax.com
News
- BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd.
- BiondVax Reports Second Quarter Financial Results and Provides Business Update
- Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Thursday
- BiondVax to Present at BIO-Europe Spring
- Stocks That Hit 52-Week Lows On Friday
- BiondVax Presenting at BIO CEO & Investor Conference
- Best Penny Stocks To Buy? 5 To Watch After Big News This Week
Your note
Sign in to keep a note on BVXV — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 49.88% | 325,974 | 488.96K | Mar 30, 2023 |
| Millennium Management Llc | 6.67% | 43,604 | 65.41K | Mar 30, 2023 |
| Virtu Financial LLC | 1.61% | 10,508 | 15.76K | Mar 30, 2023 |
| UBS Group AG | 0.81% | 5,322 | 7.98K | Mar 30, 2023 |
| Morgan Stanley | 0.35% | 2,257 | 3.38K | Mar 30, 2023 |
| Credit Agricole S.A. | 0.06% | 424 | 636 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.21% | 1,376 | 2.06K | Feb 27, 2023 |
| SPDR Portfolio Developed World ex-US ETF | 0.00% | 29 | 43 | Feb 27, 2023 |